Jun 21, 2020
Ascentage Pharma Enters Clinical Collaboration to Evaluate the Combination of Bcl-2 and BTK Inhibitors
Jun 17, 2020
Ascentage Pharma Announces First Patient Dosed in the Phase II Clinical Study of IAP Antagonist APG-1387 in Combination with Entecavir for the Treatment of Patients with Chronic Hepatitis B
May 31, 2020
(ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies
May 15, 2020
Ascentage Pharma to Present Six Abstracts at 2020 AACR Annual Meeting
Apr 07, 2020
Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 for the Treatment of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in China
Mar 29, 2020
Ascentage Pharma Releases 2019 Annual Results, Reports Increased Investment in R&D and Advances in Global Clinical Development
Mar 25, 2020
Kanazawa University Research: Insights into the Diagnosis and Treatment of Brain Cancer in Children
Mar 23, 2020
Ascentage Pharma Announces First Patient Dosed in the Global Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 in the United States
Mar 11, 2020
IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities
Mar 06, 2020
BioTheryX Appoints Professor Yinon Ben-Neriah, M.D., Ph.D., to its Scientific Advisory Board
Nov 13, 2019
PMV Pharma Secures $62 Million in Series C Financing To Develop Cancer Drugs Targeting p53
Sep 05, 2019
Theragnostics Signs Agreement with AstraZeneca
Aug 05, 2019
Aprea Therapeutics Appoints Scott Coiante as Chief Financial Officer
Jul 14, 2019
Ascentage Pharma announces first patient dosed in Phase I clinical trial of APG-2575 in China as the first China-made Bcl-2 Inhibitor
Jun 03, 2019
Ascentage Pharma presents new clinical data of apoptosis-targeted drug candidates APG-115 and APG-1387 at 2019 ASCO
May 07, 2019
New Gene Therapies Hold Out Promise for Patients
Mar 25, 2019
Ascentage Pharma Announces Nine Abstracts To Be Presented at the 2019 American Association for Cancer Research Annual Meeting
Mar 25, 2019
Aprea Therapeutics Appoints Dr. Eyal C. Attar as Chief Medical Officer
Feb 28, 2019
Theragnostics Ltd Expands Oncology Portfolio With Licensing of radioPARP Inhibitor
Jan 25, 2019
Global PARP Inhibitors in Oncology Research Report 2018: Background, Mechanism of Action, and Clinical Development of PARP Inhibitors